Search Result

Results for "

antiangiogenic factor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin Receptor (2) Apoptosis (3) c-Met/HGFR (2) CD47 (1) FGFR (2) GLUT (1) HIF/HIF Prolyl-Hydroxylase (2) MDM-2/p53 (2) NF-κB (1) PDGFR (1) Prostaglandin Receptor (2) Ras (1) TGF-β Receptor (1) TNF Receptor (1) VEGFR (4)
By Research Areas:	Cancer (12) Cardiovascular Disease (9) Endocrinology (2) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1074

Ethamsylate Etamsylate	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .

HY-17601

Alofanib 3 Publications Verification RPT835	FGFR Apoptosis	Cardiovascular Disease Cancer
Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity .

HY-P1415A

Norleual TFA 1 Publications Verification	c-Met/HGFR Angiotensin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Norleual TFA, an angiotensin (Ang) IV analog, is a *hepatocyte growth factor* (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual TFA is an AT4 receptor** antagonist and exhibits potent antiangiogenic activities .

HY-107818

4-Hydroxychalcone	NF-κB	Cardiovascular Disease Inflammation/Immunology
4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity . 4-Hydroxychalcone inhibits TNF-α induced NF-κB pathway activation and activates BMP signaling, reduces resistant hypertension (RH) by attenuating hyperaldosteronism and renal injury in mice .

HY-W011266

JNJ-10198409 1 Publications Verification	PDGFR	Cancer
JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC₅₀=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC₅₀=4.2 nM) and PDGFR-α kinase (IC₅₀=45 nM) .

HY-P1415

Norleual	c-Met/HGFR Angiotensin Receptor	Neurological Disease Metabolic Disease
Norleual, an angiotensin (Ang) IV analog, is a *hepatocyte growth factor* (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual is an AT4 receptor** antagonist and exhibits potent antiangiogenic activities .

HY-B1074R

Ethamsylate (Standard) Etamsylate (Standard)	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ethamsylate (Standard) is the analytical standard of Ethamsylate. This product is intended for research and analytical applications. Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .

HY-P10521

Apolipoprotein KV domain (67-77)	VEGFR	Cancer
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .

HY-P10833

VGB3	VEGFR	Cardiovascular Disease Cancer
VGB3 is an antagonist peptide of vascular endothelial growth factor receptor 1 (VEGFR1)/VEGFR2 with antiangiogenic and antitumor effects. VGB3 binds to both VEGFR1 and VEGFR2, thereby inhibits VEGF-driven proliferation, migration and tube formation of endothelial cells, and tumor growth and metastasis in murine 4T1 mammary carcinoma tumor model .

HY-117807

A-176120	Ras	Cancer
A-176120 is a potent inhibitor of farnesyltransferase, crucial for Ras protein farnesylation in cancer cells. It exhibits high selectivity for farnesyltransferase (IC₅₀ 1.2 ± 0.3 nM) over related enzymes like geranylgeranyltransferases and squalene synthase. Inhibition of Ras processing in H-ras and K-ras mutated cells demonstrates its efficacy in blocking Ras-mediated signaling. A-176120 shows anti-angiogenic effects by inhibiting vascular endothelial growth factor (VEGF) secretion and disrupting capillary formation in endothelial cells. In vivo studies reveal its ability to reduce tumor growth in Ras-transformed cells and enhance survival in animal models. These findings highlight A-176120 as a promising FPP analogue with potent anti-tumor and anti-angiogenic properties .

HY-B0639

Amifostine Maximum Cited Publications 7 Publications Verification WR2721	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent *hypoxia-inducible factor-α1 (HIF-α1)* and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action .

HY-B0639A

Amifostine trihydrate Maximum Cited Publications 7 Publications Verification WR2721 trihydrate	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent *hypoxia-inducible factor-α1 (HIF-α1)* and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action .

HY-101849

Fasentin 4 Publications Verification	GLUT TNF Receptor Apoptosis	Cardiovascular Disease Cancer
Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC₅₀=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .

HY-13559

Atiprimod Azaspirane	Apoptosis	Cancer
Atiprimod (Azaspirane) is an orally bioavailable small molecule with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) by inhibiting the phosphorylation of signal transducer and activator of transcription 3 (STAT3). Atiprimod also downregulates the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB transcription factors .

HY-120200

YF-452	VEGFR	Cardiovascular Disease Cancer
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .

HY-108933

JK-P3	VEGFR FGFR	Cancer
JK-P3 is a potent and pan VEGFR2 inhibitor, with IC₅₀s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively. JK-P3 can inhibit VEGF-A-stimulated VEGFR2 activation and intracellular signalling, also inhibits endothelial monolayer wound closure and angiogenesis, as well as fibroblast growth factor receptor kinase activity in vitro. JK-P3 has anti-angiogenic activity .

HY-P10388

TAX2 peptide	CD47 TGF-β Receptor	Cancer
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .

Cat. No.	Product Name	Target	Research Area

HY-P1798

Platelet Factor 4 (58-70), human	Peptides	Cardiovascular Disease
Platelet Factor 4 (58-70), human, a peptide based on the amino acid sequence corresponding to residues 58-70 of platelet factor-4 (PF-4), contains the major heparin-binding domain, which is not sufficient for full antiangiogenic activity .

HY-P1415A

Norleual TFA 1 Publications Verification	c-Met/HGFR Angiotensin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Norleual TFA, an angiotensin (Ang) IV analog, is a *hepatocyte growth factor* (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual TFA is an AT4 receptor** antagonist and exhibits potent antiangiogenic activities .

HY-P1415

Norleual	c-Met/HGFR Angiotensin Receptor	Neurological Disease Metabolic Disease
Norleual, an angiotensin (Ang) IV analog, is a *hepatocyte growth factor* (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual is an AT4 receptor** antagonist and exhibits potent antiangiogenic activities .

HY-P10521

Apolipoprotein KV domain (67-77)	VEGFR	Cancer
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .

HY-P10833

VGB3	VEGFR	Cardiovascular Disease Cancer
VGB3 is an antagonist peptide of vascular endothelial growth factor receptor 1 (VEGFR1)/VEGFR2 with antiangiogenic and antitumor effects. VGB3 binds to both VEGFR1 and VEGFR2, thereby inhibits VEGF-driven proliferation, migration and tube formation of endothelial cells, and tumor growth and metastasis in murine 4T1 mammary carcinoma tumor model .

HY-P10388

TAX2 peptide	CD47 TGF-β Receptor	Cancer
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .

4-Hydroxychalcone	Cardiovascular Disease Structural Classification Chalcones Monophenols Flavonoids other families Classification of Application Fields Source classification Phenols Plants Disease Research Fields	NF-κB
4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity . 4-Hydroxychalcone inhibits TNF-α induced NF-κB pathway activation and activates BMP signaling, reduces resistant hypertension (RH) by attenuating hyperaldosteronism and renal injury in mice .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

antiangiogenic factor

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products